Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2018-04-12 Regulatory Filings
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 12, 2018. It announces a press release about new clinical trial data from the company. The document is short (3305 characters) and primarily serves to disclose a press release rather than provide detailed financial data or a full report. It explicitly states that the information is furnished and not filed for purposes of Section 18, indicating it is an announcement rather than a full report. There are no financial statements or substantive financial analysis included. Therefore, this document fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and announcements that do not fit other specific categories.
2018-04-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 11, 2018. It announces a presentation poster (Exhibit 99.1) related to clinical trial data to be presented at a medical conference. The document explicitly states that the presentation poster is attached as an exhibit and that the information is furnished and not filed, indicating it is an announcement of a presentation rather than the presentation itself. The content is regulatory in nature, providing disclosure under Regulation FD, and does not contain financial statements or detailed financial data. The document length is 3551 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-04-12 English
FORM 4
Director's Dealing
2018-03-26 English
FORM 3
Director's Dealing
2018-03-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2018, reporting the appointment of a new director, Ivana Magovcevic-Liebisch, to the Board of Directors and her compensation details. The content focuses on changes in the company's board and management, including stock option grants and indemnification agreements. There is no financial data or report attached, nor is it an announcement of a report publication. The primary subject is a management change, fitting the category of Board/Management Information (MANG). The document length is 3851 characters, which is typical for an 8-K filing of this nature and not a full report or earnings release.
2018-03-26 English
Regulatory Filings 2018
Regulatory Filings
2018-03-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.